RT Journal Article
SR Electronic
T1 SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e001496
DO 10.1136/jitc-2020-001496
VO 9
IS 3
A1 Redin, Esther
A1 Garmendia, Irati
A1 Lozano, Teresa
A1 Serrano, Diego
A1 Senent, Yaiza
A1 Redrado, Miriam
A1 Villalba, Maria
A1 De Andrea, Carlos E
A1 Exposito, Francisco
A1 Ajona, Daniel
A1 Ortiz-Espinosa, Sergio
A1 Remirez, Ana
A1 Bertolo, Cristina
A1 Sainz, Cristina
A1 Garcia-Pedrero, Juana
A1 Pio, Ruben
A1 Lasarte, Juan
A1 Agorreta, Jackeline
A1 Montuenga, Luis M
A1 Calvo, Alfonso
YR 2021
UL http://jitc.bmj.com/content/9/3/e001496.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.